Related Articles
Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma
DNA topoisomerase IIα (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: In vitro evidence for a ‘functional amplicon’ involving FAS, Her-2/neu and TOP2A genes
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients
Anticancer immune reactivity and long‑term survival after treatment of metastatic ovarian cancer with dendritic cells